Pharmacogenomics of Adverse Drug Reactions: Practical Applications and Perspectives

• Lazarou J , PomeranzBH, CoreyPN: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.JAMA279 , 1200–1205 (1998).
   PubMed Web of Science ®Google Scholar
• Moore T , CohenM, FurbergC: Serious adverse drug events reported to the food and drug administration, 1998–2005.Arch. Intern. Med.167 , 1752–1759 (2008).
   Google Scholar
• Pirmohamed M , JamesS, MeakinS et al.: Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients.BMJ329 , 15–19 (2004).
   PubMed Web of Science ®Google Scholar
• DiMasi J : Risks in new drug development: approval success rates for investigational drugs.Clin. Pharmacol. Ther.69 , 297–307 (2001).
   PubMed Web of Science ®Google Scholar
• Wysowski D , SwartzL: Adverse drug event surveillance and drug withdrawals in the United States, 1969–2002.Arch. Intern. Med.165 , 1363–1369 (2005).
   PubMed Web of Science ®Google Scholar
• Meyer UA : Pharmacogenetics – five decades of therapeutic lessons from genetic diversity.Nat. Rev. Genet.5 , 669–675 (2004).
   PubMed Web of Science ®Google Scholar
• Frueh F , AmurS, MummaneniP et al.: Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use.Pharmacotherapy28 , 992–998 (2008).
   PubMed Web of Science ®Google Scholar
• Wilke R , LinD, RodenD et al.: Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges.Nat. Rev. Drug Discov.6 , 904–916 (2007).
   PubMed Web of Science ®Google Scholar
• Colhoun HM , McKeiguePM, Davey Smith G: Problems of reporting genetic associations with complex outcomes. Lancet361 , 865–872 (2003).
   PubMed Web of Science ®Google Scholar
• Anderson J , HorneB, StevensS et al.: Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation.Circulation116 , 2563–2570 (2007).
   PubMed Web of Science ®Google Scholar
• Behre H , GrebR, MempelA et al.: Significance of a common single nucleotide polymorphism in exon 10 of the follicle-stimulating hormone (FSH) receptor gene for the ovarian response to FSH: a pharmacogenetic approach to controlled ovarian hyperstimulation.Pharmacogenet. Genomics15 , 451–456 (2005).
   PubMed Web of Science ®Google Scholar
• Caraco Y , BlotnickS, MuszkatM: CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study.Clin. Pharmacol. Ther.83 , 460–470 (2008).
   PubMed Web of Science ®Google Scholar
• Furuta T , ShiraiN, KodairaM et al.: Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori.Clin. Pharmacol. Ther.81 , 521–528 (2007).
   PubMed Web of Science ®Google Scholar
• Hillman MA , WilkeRA, YaleSH et al.: A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data.Clin. Med. Res.3 , 137–145 (2005).
   PubMedGoogle Scholar
• Mallal S , PhillipsE, CarosiG et al.: HLA-B*5701 screening for hypersensitivity to abacavir.N. Engl. J. Med.358 , 568–579 (2008).
   PubMed Web of Science ®Google Scholar
• Quteineh L , VerstuyftC, FurlanV et al.: Influence of CYP3A5 genetic polymorphism on tacrolimus daily requirements, acute rejection and nephrotoxicity in renal graft recipients.Basic Clin. Pharmacol. Toxicol.103 , 546–552 (2008).
   PubMed Web of Science ®Google Scholar
• Macphee I , FredericksS, TaiT et al.: Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement.Transplantation74 , 1486–1489 (2002).
   PubMed Web of Science ®Google Scholar
• Anglicheau D , LegendreC, BeauneP, ThervetE: Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update.Pharmacogenomics8 , 835–849 (2007).
   PubMed Web of Science ®Google Scholar
• Llerena A , MichelG, JeannessonE et al.: Third Santorini conference pharmacogenomics workshop report: ‘Pharmacogenomics at the crossroads: what else than good science will be needed for the field to become part of Personalized Medicine?‘Clin. Chem. Lab. Med.45 , 843–850 (2007).
   PubMedGoogle Scholar
• Owen R , KleinT, AltmanR: The education potential of the pharmacogenetics and pharmacogenomics knowledge base (PharmGKB).Clin. Pharmacol. Ther.82 , 472–475 (2007).
   PubMed Web of Science ®Google Scholar
• Patel K , BabyatskyM: Medical education: a key partner in realizing personalized medicine in gastroenterology.Gastroenterology134 , 656–661 (2008).
   PubMed Web of Science ®Google Scholar
• Shields A , LermanC: Anticipating clinical integration of pharmacogenetic treatment strategies for addiction: are primary care physicians ready?Clin. Pharmacol. Ther.83 , 635–639 (2008).
   PubMed Web of Science ®Google Scholar
• Deverka P , McLeodH: Harnessing economic drivers for successful clinical implementation of pharmacogenetic testing.Clin. Pharmacol. Ther.84 , 191–193 (2008).
   PubMed Web of Science ®Google Scholar
• Vegter S , BoersmaC, RozenbaumM, WilffertB, NavisG, PostmaM: Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines.Pharmacoeconomics26 , 569–587 (2008).
   PubMed Web of Science ®Google Scholar
• Criswell LA , LumRF, TurnerKN et al.: The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept.Arthritis Rheum.50 , 2750–2756 (2004).
   PubMed Web of Science ®Google Scholar
• Ferrell P , McLeodH: Carbamazepine, HLA-B*1502 and risk of Stevens–Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations.Pharmacogenomics9 , 1543–1546 (2008).
   PubMed Web of Science ®Google Scholar
• Hung S , ChungW, LiouL et al.: HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.Proc. Natl Acad. Sci. USA102 , 4134–4139 (2005).
   PubMed Web of Science ®Google Scholar
• Gatanaga H , HondaH, OkaS: Pharmacogenetic information derived from analysis of HLA alleles.Pharmacogenomics9 , 207–214 (2008).
   PubMed Web of Science ®Google Scholar
• Young B , SquiresK, PatelP et al.: First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America.AIDS22 , 1673–1675 (2008).
   PubMed Web of Science ®Google Scholar
• Rauch A , NolanD, MartinA, McKinnonE, AlmeidaC, MallalS: Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study.Clin. Infect. Dis.43 , 99–102 (2006).
   PubMed Web of Science ®Google Scholar
• Zucman D , TruchisP, MajerholcC, StegmanS, Caillat-ZucmanS: Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population.J. Acquir. Immune Defic. Syndr.45 , 1–3 (2007).
   PubMed Web of Science ®Google Scholar
• Schackman B , ScottC, WalenskyR, LosinaE, ReedbergK, SaxP: The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV.AIDS22 , 2025–2033 (2008).
   PubMed Web of Science ®Google Scholar
• Horton R , WilmingL, RandV et al.: Gene map of the extended major histocompatibility complex.Nat. Rev. Genet.5 , 889–899 (2004).
   PubMed Web of Science ®Google Scholar
• Ingelman -Sundberg M: Pharmacogenomic biomarkers for prediction of severe adverse dreug reactions. N. Engl. J. Med.358 , 637–639 (2008).
   PubMed Web of Science ®Google Scholar
• Klein R : Power analysis for genome-wide association studies.BMC Genet.8 , 58 (2007).
   PubMed Web of Science ®Google Scholar
• Li Q , ZhengG, LiZ, YuKS: Efficient approximation of p-value of the maximum of correlated tests, with applications to genome-wide association studies.Ann. Hum. Genet.72 , 397–406 (2008).
   PubMed Web of Science ®Google Scholar
• Nelson M , Bacanu S-A, Mosteller M et al.: Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions. Pharmacogenomics J.9 , 23–33 (2008).
   PubMed Web of Science ®Google Scholar
• Link E , ParishS, ArmitageJ et al.: SLCO1B1 variants and statin-induced myopathy – a genomewide study.N. Engl. J. Med.359 , 789–799 (2008).
   PubMed Web of Science ®Google Scholar
• Kameyama Y , YamashitaK, KobayashiK, HosokawaM, ChibaK: Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells.Pharmacogenet. Genomics15 , 513–522 (2005).
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ , BackmanJT, NiemiM: Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.Clin. Pharmacokinet.47 , 463–474 (2008).
   PubMed Web of Science ®Google Scholar
• Pasanen MK , NeuvonenM, NeuvonenPJ, NiemiM: SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid.Pharmacogenet. Genomics16 , 873–879 (2006).
   PubMed Web of Science ®Google Scholar
• Wolfberg A : Genes on the Web – direct-to-consumer marketing of genetic testing.N. Engl. J. Med.345 , 543–545 (2006).
   Google Scholar
• Mega J , CloseS, WiviottS et al.: Cytochrome p-450 polymorphisms and response to clopidogrel.N. Engl. J. Med.360 , 354–362 (2009).
   PubMed Web of Science ®Google Scholar
• Simon T , VerstuyftC, Mary-KrauseM et al.: Genetic determinants of response to clopidogrel and cardiovascular events.N. Engl. J. Med.360 , 363–375 (2009).
   PubMed Web of Science ®Google Scholar
• Mardis E : The impact of next-generation sequencing technology on genetics.Trends Genet.24 , 133–141 (2008).
   PubMed Web of Science ®Google Scholar
• Chung W , HungS, HongH et al.: Medical genetics: a marker for Stevens–Johnson syndrome.Nature428 , 486 (2004).
   PubMed Web of Science ®Google Scholar
• Donaldson P , BhatnagarP, GrahamJ et al.: Flucloxacillin-induced liver injury: the extended MHC 57.1 haplotype as a major risk factor.Hepatology48 , 396A–397A (2008).
   Web of Science ®Google Scholar
• Hoskins J , GoldbergR, QuP, IbrahimJ, McLeodH: UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.J. Natl Cancer Inst.99 , 1290–1295 (2007).
   PubMed Web of Science ®Google Scholar
• Côté J , KirzinS, KramarA et al.: UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan.J. Clin. Oncol.13 , 3269–3275 (2007).
   Google Scholar
• Martin A , NolanD, JamesI et al.: Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts.AIDS19 , 97–99 (2005).
   PubMed Web of Science ®Google Scholar
• Littera R , CarcassiC, MasalaA et al.: HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients.AIDS20 , 1624–1626 (2006).
   Web of Science ®Google Scholar
• Quteineh L , VerstuyftC, DescotC et al.: Vitamin K epoxide reductase (VKORC1) genetic polymorphism is associated to oral anticoagulant overdose.Thromb. Haemost.94 , 690–691 (2005).
   PubMed Web of Science ®Google Scholar
• Lucena M , AndradeR, MartínezC et al.: Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury.Hepatology48 , 588–596 (2009).
   Web of Science ®Google Scholar
• Daly A , AithalG, LeathartJ, SwainsburyR, DangT, DayC: Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes.Gastroenterology132 , 272–281 (2007).
   PubMed Web of Science ®Google Scholar
• Huang YS , ChernH, SuWJ et al.: Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis.Hepatology35 , 883–889 (2002).
   PubMed Web of Science ®Google Scholar
• Possuelo L , CastelanJ, de Brito T et al.: Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil. Eur. J. Clin. Pharmacol.64 , 673–681 (2008).
   PubMed Web of Science ®Google Scholar
• Kindmark A , JawaidA, HarbronC et al.: Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis.Pharmacogenomics J.8 , 186–195 (2008).
   PubMed Web of Science ®Google Scholar
• Simon T , BecquemontL, Mary-KrauseM et al.: Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity.Clin. Pharmacol. Ther.67 , 432–437 (2000).
   PubMed Web of Science ®Google Scholar

▪ Websites

• Tacrolimus in renal transplantation: individualization by pharmacogenetic www.clinicaltrials.gov/ct2/show/NCT00552201
   Google Scholar
• Registry of federally and privately supported clinical trials conducted in the USA and around the world www.clinicaltrials.gov
   Google Scholar
• International warfarin pharmacogenetics consortium. Provides an algorithm which predicts the warferin daily dose requirement based on pharmacogenetic and clinical factors www.warfarindosing.org
   Google Scholar
• US FDA Center of Drug Evaluation and Research where the drug product characteristics, including pharmacogenomics labels, are updated www.fda.gov/cder/genomics/
   Google Scholar
• European Medicines Agency www.emea.europa.eu/
   Google Scholar